Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pirtobrutinib

FDA-approved product (tablet, oral), marketed as Jaypirca.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pirtobrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mantle cell lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pirtobrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pirtobrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).

    NCT07784101 · start 2026-10

    Registered record
    Registry ID
    NCT07784101
    Conditions
    Relapsed or Refractory Mantle Cell Lymphoma (MCL)
    Interventions
    ICP-248; Pirtobrutinib; Orelabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2033-12
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory Mantle Cell Lymphoma (MCL)
    InterventionICP-248; Pirtobrutinib; Orelabrutinib
    PhasePhase 3
    Registry statusNot yet recruiting

  • Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor

    NCT07796373 · start 2026-09-24

    Registered record
    Registry ID
    NCT07796373
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
    Interventions
    Nemtabrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-24
    Completion
    2031-12-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Leukemia
    InterventionNemtabrutinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).

    NCT07624799 · start 2026-09-01

    Registered record
    Registry ID
    NCT07624799
    Conditions
    CLL (Chronic Lymphocytic Leukemia)
    Interventions
    Pirtobrutinib; Fludarabine; Cyclophosphamide; Obinutuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2033-09-01
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCLL (Chronic Lymphocytic Leukemia)
    InterventionPirtobrutinib; Fludarabine; Cyclophosphamide; Obinutuzumab
    PhasePhase 2
    Registry statusNot yet recruiting

  • Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement

    NCT07812493 · start 2026-09-01

    Registered record
    Registry ID
    NCT07812493
    Conditions
    Pirtobrutinib; Immunochemotherapy; DLBCL - Diffuse Large B Cell Lymphoma; CNS Involvement of Systemic Lymphoma
    Interventions
    pirtobrutinib+MTX+immunolchemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2030-09-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPirtobrutinib; Immunochemotherapy; DLBCL - Diffuse Large B Cell Lymphoma; CNS Involvement of Systemic Lymphoma
    Interventionpirtobrutinib+MTX+immunolchemotherapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma

    NCT07744750 · start 2026-08-30

    Registered record
    Registry ID
    NCT07744750
    Conditions
    DLBCL - Diffuse Large B Cell Lymphoma; Richter Transformation; CLL / SLL; MZL
    Interventions
    Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08-30
    Completion
    2029-08-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDLBCL - Diffuse Large B Cell Lymphoma; Richter Transformation; CLL / SLL; MZL
    InterventionPirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma
    PhasePhase 2
    Registry statusNot yet recruiting

  • Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

    NCT07516093 · start 2026-08-03

    Registered record
    Registry ID
    NCT07516093
    Conditions
    B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    NX-5948; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-08-03
    Completion
    2033-08
    Enrolment
    620

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionNX-5948; Pirtobrutinib
    PhasePhase 3
    Registry statusRecruiting

  • Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia

    NCT07685717 · start 2026-08-01

    Registered record
    Registry ID
    NCT07685717
    Conditions
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Electronic Health Record Review; Pirtobrutinib; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-01
    Completion
    2027-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL

    NCT07744737 · start 2026-07-30

    Registered record
    Registry ID
    NCT07744737
    Conditions
    DLBCL - Diffuse Large B Cell Lymphoma; R-CHOP Chemotherapy; Pirtobrutinib
    Interventions
    Pirtobrutinib plus R-CHOP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-30
    Completion
    2029-04-30
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDLBCL - Diffuse Large B Cell Lymphoma; R-CHOP Chemotherapy; Pirtobrutinib
    InterventionPirtobrutinib plus R-CHOP
    PhasePhase 2
    Registry statusNot yet recruiting

  • Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma

    NCT07622784 · start 2026-06

    Registered record
    Registry ID
    NCT07622784
    Conditions
    Relapsed or Refractory B-cell Lymphoma
    Interventions
    Pirtobrutinib; Second Infusion of Commercial Anti-CD19 CAR-T Cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-06
    Completion
    2028-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed or Refractory B-cell Lymphoma
    InterventionPirtobrutinib; Second Infusion of Commercial Anti-CD19 CAR-T Cells
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma

    NCT07525817 · start 2026-04-01

    Registered record
    Registry ID
    NCT07525817
    Conditions
    Mature B-Cell Lymphoma
    Interventions
    Pirtobrutinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-04-01
    Completion
    2028-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMature B-Cell Lymphoma
    InterventionPirtobrutinib
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

    NCT07428707 · start 2026-03-11

    Registered record
    Registry ID
    NCT07428707
    Conditions
    Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2026-03-11
    Completion
    2030-03-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
    InterventionPirtobrutinib
    PhaseEarly phase 1
    Registry statusRecruiting

  • A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT07218341 · start 2026-03-09

    Registered record
    Registry ID
    NCT07218341
    Conditions
    Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
    Interventions
    Pirtobrutinib; Idelalisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-09
    Completion
    2032-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
    InterventionPirtobrutinib; Idelalisib
    PhasePhase 4
    Registry statusRecruiting

  • PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

    NCT07207785 · start 2026-02-01

    Registered record
    Registry ID
    NCT07207785
    Conditions
    Mantle Cell Lymphoma
    Interventions
    Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-02-01
    Completion
    2030-02-01
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMantle Cell Lymphoma
    InterventionPirtobrutinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Mosunetuzumab for CLL MRD Clearance

    NCT07052695 · start 2025-11-24

    Registered record
    Registry ID
    NCT07052695
    Conditions
    Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
    Interventions
    Mosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2025-11-24
    Completion
    2032-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoma
    InterventionMosunetuzumab; Ibrutinib; Acalabrutinib; Zanubrutinib +1 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

    NCT06948786 · start 2025-11-17

    Registered record
    Registry ID
    NCT06948786
    Conditions
    Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma
    Interventions
    Pirtobrutinib; Mosunetuzumab; Biospecimen Collection; Biopsy Procedure; Computed Tomography; Positron Emission Tomography; Bone Marrow Aspiration; Bone Marrow Biopsy; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-11-17
    Completion
    2031-07-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGrade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma +1 more
    InterventionPirtobrutinib; Mosunetuzumab; Biospecimen Collection; Biopsy Procedure +5 more
    PhasePhase 2
    Registry statusRecruiting